Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2023 unaudited financial results.
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights Read More »
HeartBeam, Inc. today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its HeartBeam AIMIGo™ System.
HeartBeam Announces FDA Submission of HeartBeam AIMIGo™ VECG System Read More »
Teva Pharmaceutical Industries Ltd. today announced a new strategic framework with four main pillars to position the Company for a new era of growth.
Protalix BioTherapeutics, Inc. today announced that it is eligible to receive a $20 million milestone payment from its commercial partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group.
BD (Becton, Dickinson and Company) announced the worldwide commercial launch of a new-to-world cell sorting instrument featuring two breakthrough technologies that enable researchers to uncover more detailed information about cells that was previously invisible in traditional flow cytometry experiments.
BD Launches World’s First Spectral Cell Sorter with High-Speed Cell Imaging Read More »
Affinia Therapeutics today announced the presentation of new preclinical data on novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS).
Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload.
Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a previously published prospective, randomized study more than 1,000 patients aimed at evaluating the clinical utility of the ExoDx™ Prostate Test over a 5-year follow-up period.
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented positive Phase 1 clinical data from its lead program, KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader.
Orchard Therapeutics today presented new data from the company’s hematopoietic stem cell (HSC) gene therapy research pipeline targeting larger indications at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.
